Dr. Foster:Here is a current journal article -- and the abstract promotes the idea that all TNF biologics work in uveitis.
My son was on Enbrel for 3 years with no results -- and the rheumatologist was well-meaning but had no/little contact with uveitis. Dr Read at UAB took him off Enbrel & his eye has been quiet for >4 months. My son's experience with Enbrel is not definitive, but it seems to coincide with a growing number of patients with similar experiences.
What do you think of this abstract? Is there anything we can do about it?
Clinical Efficacy of TNF-α Inhibitors: An Update
Posted: 05/19/2010; Int J Clin
Rheum. 2010;5(1):101-115. © 2010 Future Medicine Ltd
AbstractOver the last decade, TNF-α antagonists became the most powerful tools for controlling patient suffering from a number of rheumatic diseases. Infliximab, etanercept and adalimumab can induce remission and prevent both clinical and radiological disease progression in rheumatoid arthritis with significant improvement in patients' symptoms, function and quality of life. They improve joint symptoms and significantly retard radiographic progression in psoriatic arthritis. TNF-α antagonists have been demonstrated to reduce disease activity, retard radiologic progression and increase quality of life in ankylosing spondylitis patients. Long-term follow-up studies demonstrated sustained efficacy and acceptable safety profiles that were comparable in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Etanercept is the only US FDA-approved TNF antagonist for juvenile rheumatoid arthritis. TNF-α antagonists may improve some clinical manifastations of Behçet's disases, including uveitis.